Open AccessSelective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases
Author(s) -
Nadire Duru,
Nisha R. Pawar,
Erik W. Martin,
Marguerite S. Buzza,
Gregory D. Conway,
Rena G. Lapidus,
Shihui Liu,
Jocelyn Reader,
Gautam Rao,
Dana M. Roque,
Stephen H. Leppla,
Toni M. Antalis
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2201423119
Subject(s) - ovarian cancer , proteases , cancer research , ovarian tumor , anthrax toxin , cytotoxic t cell , cancer , medicine , prodrug , in vivo , biology , pharmacology , in vitro , biochemistry , enzyme , fusion protein , recombinant dna , microbiology and biotechnology , gene